Novavax used a conventional technology to develop a vaccine, which has slowed development and approval. But there is still time for it to make some big sales.

How high can the share price of pharmaceutical company Novavax go? That's the question investors should be asking themselves as they evaluate the Gaithersburg, Maryland-based company. NVAX stock has been on a tear lately, rising 29% in the past month and up 116% year-to-date. The share price is now flirting with $250.00, begging the question: Does the stock have more runway ahead of it

While NVAX stock works its way towards all-time highs, traders should prepare for a breakout as Novavax makes headway in vaccine development.

When it ships an approved Covid-19 vaccine, Novavax is poised for sharp growth for many quarters, as countries grapple to vaccinate people.

For retail traders seeking short-term profits, NVAX stock is looking interesting once again. However, it's not a good long-term investment.

RA Capital Management is a large Novavax shareholder. It owns 5.1% of NVAX stock. In Q2 2021 it reduced its position slightly. Time to worry?  

Novavax's Covid-19 vaccine has strong potential outside the U.S and will generate revenue. This dip is a chance to buy NVAX stock.

Maryland-based Novavax made immense progress of late, which positions NVAX stock as one of the most promising in the biotech space.